JeniVision is an early clinical stage biopharmaceutical company that strives to discover & develop innovative therapies in ophthalmology. Our proprietary non-invasive ocular delivery pathway (NIODP) enables successful drug delivery to the retina with high bioavailability. We have candidates in preclinical and clinical stages to not only treat debilitating diseases such as glaucoma and dry eye, but also prevent most common vision loss diseases like ROP, myopia and AMD. We believe that our innovative, non-invasive treatment for dry AMD will not only improve patient’s vision, but also prevent these patients from developing blinding wet AMD disease. With our creativity and ingenuity, we hope to forge new pathways in medicine for the future.
09/21/2023: JENIVISION CEO, DR. JENNY WANG, INTERVIEWED AT THE 2023 OCTANE HIGH TECH AWARDS. The insightful conversation is conducted by seasoned business journalist Jane King of the NASDAK MarketSite. The interview delved into JeniVision's groundbreaking work and vision for the future, showcasing the company's dedication to excellence and innovation in ophthalmic pharmaceuticals. The recorded interview is now accessible on YouTube via the following link. A detailed summary of the discussion can be found on LinkedIn.
@ 2023 Octane High Tech Awards
Nonna & Jenny
09/18/2023: JeniVision is pleased to announce the publication of our discovery of an innovative ocular delivery platform (NIODP). The manuscript entitled "Discovery and Potential Utility of a Novel Non-Invasive Ocular Delivery Platform", is published as an invited contribution for a special topic on "New Challenges in Ocular Drug Delivery" in Pharmaceutics (IF 6.525, 2022-2023). Please click the link or scan the QR code above for further reading.
June of 2022, JeniVision Receives Rare Pediatric Disease Designation from U.S. FDA for JV-MD2 (Omega-3 DHA) in Prevention of Retinopathy of Prematurity (ROP). JeniVision has been granted the Rare Pediatric Disease Designation by the U.S. Food and Drug Administration for JV-MD2 (omega-3 DHA), delivered by their proprietary Non-Invasive Ocular Delivery Platform (NIODP). This designation signifies the FDA's recognition of JV-MD2's potential in preventing Retinopathy of Prematurity (ROP), a serious eye condition affecting premature infants.
Jenny Wang, PhD, CEO/CSO, is an entrepreneur, an inventor, and a scientist. She also serves as Executive Chairwomen of the JeniVision Board of Directors. She leads and executes business plans for obtaining financing, establishing partnerships, IND filings and intellectual property protection efforts of JeniVision; as well as spearheads pre-clinical research & development, including research, design, and formulation development for JeniVision pipeline. Through these various activities, Dr. Wang led the discovery of the proprietary non-invasive ocular delivery pathway (NIODP). Under the leadership of Dr. Wang, the company expanded the pipeline for treatment of major ophthalmic diseases to include not only the anterior but also the posterior segments of the eye. Dr. Wang is well-trained in pharmacology, biochemistry, and molecular & cellular biology. She brings over 30-years of experience in academia and pharmaceutical/biotechnology industry, including positions at City of Hope, California Institute of Technology, and Allergan. Her success as a researcher and inventor is evident in over 45 peer reviewed scientific publications and over 45 patents on cancer, ion channel, inflammation, ophthalmology, and hair growth. https://www.linkedin.com/in/dr-jennywwang
Nonna Snider, VP Clinical & Operations, joined JeniVision in 2020. She leads clinical research, manages FDA filings, and helps with day-to-day company operations. She has over 20 years of experience in pre-clinical and clinical drug development in both Pharmaceutical Industry and Academia. Mrs. Snider started her research career at Allergan in the Nuclear Receptor group focused on drug discovery in the areas of dermatology, oncology and metabolic disease. She then transitioned to project management in a biotech start-up environment, gaining experience in conducting pre-clinical and clinical research in US, India and Latin America, taking a dermatology and oncology compounds through pre-clinical, Phase I and II clinical trials. Mrs. Snider then joined USC Norris Comprehensive Cancer Center team coordinating Quality Assurance and Data and Safety Monitoring Committees, working within a multidisciplinary team to further grow the QA and DSM programs, and later as the Assistant Director for Clinical Operations at CISO, and was responsible for ensuring safe and compliant implementation of Phase I, II and III oncology clinical trials conducted at USC. https://www.linkedin.com/in/nonna-snider-sheynkman-01b0084